Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1977-07-22
1978-10-03
Phillips, Delbert R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
2601125R, 1951035R, A61K 3702, C07C10352
Patent
active
041184823
ABSTRACT:
Modified actinomycin compounds that incorporate azetidine in the polypeptide component of the actinomycin molecule are disclosed. These compounds are called azetomicins and specifically incorporate an azetidine derivative in the 3' peptide position in at least one of the two polypeptides normally present in actinomycins. The azetomicins are produced by bio-synthetic means from Streptomyces antibioticus that are cultured on a medium including azetidine-2 carboxylic acid and derivatives thereof.
REFERENCES:
patent: 4053460 (1977-10-01), Apple et al.
Apple Martin A.
Formica Joseph V.
Phillips Delbert R.
The Regents of the University of California
LandOfFree
Process for treating neoplastic disease with azetomicins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for treating neoplastic disease with azetomicins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for treating neoplastic disease with azetomicins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1802014